Press Room

News / Jan 22, 2019

Diane Villax receives the Officer’s Cross of the Order of Merit of Hungary

The decoration was handed to Mrs. Villax by the Hungarian Ambassador to Portugal, Madame Klára Breuer, conferred on her by the President of the Republic of Hungary.

Diane Villax receives the Officer s Cross of the Order of Merit of Hungary | Hovione

On January 22nd Mrs. Diane Villax, Founder Chairman, received the Officer’s Cross of the Order of Merit of Hungary. The decoration was handed to Mrs. Villax by the Hungarian Ambassador to Portugal, Madame Klára Breuer, conferred on her by the President of the Republic of Hungary in recognition of the contribution to the development of education of Chemical Engineers through helping students of the Budapest Technical University financially and professionally.

The ceremony took place at the Hungarian Embassy in Lisbon and was attended by representatives of the Embassy, the Portuguese Government, Hovione, friends and members of the Villax family.

Diane Villax receives the Officer’s Cross of the Order of Merit of Hungary | Hovione
Madame Klára Breuer, the Hungarian Ambassador to Portugal, and Diane Villax, Founder Chairman of Hovione.

Since 1993, Hovione has received graduate students from the Faculty of Chemical Technology and Biotechnology of the Budapest University of Technology and Economics, alma mater of Dr. Ivan Villax. In 2008, a protocol was signed between the University and Hovione, which pledges to annually receive one to two students in the area of R&D, giving them financial and professional support.

It was an intimate ceremony and Mrs. Villax expressed her appreciation of the award saying “this is the story of how the traineeship program came about and which is the basis of the honour I have received today. All I have to say is thank you very much and we intend to continue, our tag line "In it for Life" with many interpretations”.

 

Learn more about the Ivan Villax Traineeship

 

 

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025